vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Ascendis Pharma A/S (ASND). Click either name above to swap in a different company.
Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $247.1M, roughly 1.1× ANI PHARMACEUTICALS INC). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 29.6%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 34.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Ascendis Pharma A/SASNDEarnings & Financial Report
Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.
ANIP vs ASND — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $267.3M |
| Net Profit | $27.5M | — |
| Gross Margin | — | 90.5% |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 42.3% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $267.3M | ||
| Q3 25 | $227.8M | $230.7M | ||
| Q2 25 | $211.4M | $170.7M | ||
| Q1 25 | $197.1M | $109.0M | ||
| Q4 24 | $190.6M | $187.8M | ||
| Q3 24 | $148.3M | $62.5M | ||
| Q2 24 | $138.0M | $38.9M | ||
| Q1 24 | $137.4M | $103.6M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $-65.9M | ||
| Q2 25 | $8.5M | $-42.0M | ||
| Q1 25 | $15.7M | $-102.2M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $-107.1M | ||
| Q2 24 | $-2.3M | $-118.1M | ||
| Q1 24 | $18.2M | $-141.5M |
| Q4 25 | — | 90.5% | ||
| Q3 25 | — | 89.5% | ||
| Q2 25 | — | 80.1% | ||
| Q1 25 | — | 82.6% | ||
| Q4 24 | — | 91.9% | ||
| Q3 24 | — | 80.6% | ||
| Q2 24 | — | 68.2% | ||
| Q1 24 | — | 92.1% |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 5.1% | ||
| Q2 25 | 6.6% | -33.5% | ||
| Q1 25 | 13.3% | -103.2% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | -167.3% | ||
| Q2 24 | 3.7% | -370.2% | ||
| Q1 24 | 14.8% | -51.2% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | -28.5% | ||
| Q2 25 | 4.0% | -24.6% | ||
| Q1 25 | 8.0% | -93.7% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | -171.5% | ||
| Q2 24 | -1.7% | -303.9% | ||
| Q1 24 | 13.2% | -136.6% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $665.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $-175.8M |
| Total Assets | $1.4B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $665.3M | ||
| Q3 25 | $262.6M | $582.2M | ||
| Q2 25 | $217.8M | $533.6M | ||
| Q1 25 | $149.8M | $559.4M | ||
| Q4 24 | $144.9M | $604.3M | ||
| Q3 24 | $145.0M | $675.6M | ||
| Q2 24 | $240.1M | $279.4M | ||
| Q1 24 | $228.6M | $345.9M |
| Q4 25 | $540.7M | $-175.8M | ||
| Q3 25 | $505.8M | $-188.0M | ||
| Q2 25 | $436.8M | $-202.6M | ||
| Q1 25 | $418.6M | $-205.0M | ||
| Q4 24 | $403.7M | $-114.2M | ||
| Q3 24 | $405.9M | $-105.1M | ||
| Q2 24 | $455.8M | $-346.8M | ||
| Q1 24 | $452.0M | $-257.2M |
| Q4 25 | $1.4B | $1.4B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.1B | ||
| Q4 24 | $1.3B | $1.3B | ||
| Q3 24 | $1.3B | $1.2B | ||
| Q2 24 | $920.8M | $819.0M | ||
| Q1 24 | $914.5M | $866.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $58.2M |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $58.2M | ||
| Q3 25 | $44.1M | — | ||
| Q2 25 | $75.8M | — | ||
| Q1 25 | $35.0M | $-15.5M | ||
| Q4 24 | $15.9M | $-330.7M | ||
| Q3 24 | $12.5M | — | ||
| Q2 24 | $17.4M | — | ||
| Q1 24 | $18.3M | $-109.7M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
ASND
Segment breakdown not available.
